NYSE:ENOV Enovis (ENOV) Stock Price, News & Analysis $28.44 +2.69 (+10.42%) Closing price 08/7/2025 03:59 PM EasternExtended Trading$28.53 +0.09 (+0.30%) As of 08/7/2025 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Enovis Stock (NYSE:ENOV) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Enovis alerts:Sign Up Key Stats Today's Range$26.90▼$29.5650-Day Range$25.74▼$35.9452-Week Range$25.47▼$49.83Volume1.70 million shsAverage Volume1.59 million shsMarket Capitalization$1.62 billionP/E RatioN/ADividend YieldN/APrice Target$57.00Consensus RatingBuy Company Overview Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware. Read More Enovis Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreENOV MarketRank™: Enovis scored higher than 67% of companies evaluated by MarketBeat, and ranked 403rd out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingEnovis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEnovis has only been the subject of 2 research reports in the past 90 days.Read more about Enovis' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth14.34% Earnings GrowthEarnings for Enovis are expected to grow by 14.34% in the coming year, from $2.79 to $3.19 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enovis is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enovis is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnovis has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted13.29% of the float of Enovis has been sold short.Short Interest Ratio / Days to CoverEnovis has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Enovis has recently decreased by 6.31%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEnovis does not currently pay a dividend.Dividend GrowthEnovis does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.29% of the float of Enovis has been sold short.Short Interest Ratio / Days to CoverEnovis has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Enovis has recently decreased by 6.31%, indicating that investor sentiment is improving significantly. News and Social Media2.5 / 5News Sentiment0.51 News SentimentEnovis has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Enovis this week, compared to 6 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Enovis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.70% of the stock of Enovis is held by insiders.Percentage Held by Institutions98.45% of the stock of Enovis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Enovis' insider trading history. Receive ENOV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enovis and its competitors with MarketBeat's FREE daily newsletter. Email Address ENOV Stock News HeadlinesEnovis Corporation (ENOV) Q2 2025 Earnings Call Transcript1 hour ago | seekingalpha.comEnovis Corporation Reports 7% Sales Growth in Q2 2025, Driven by 11% Increase in Reconstructive SalesAugust 7 at 6:15 AM | quiverquant.comQAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation. | Paradigm Press (Ad)Enovis Announces Second Quarter 2025 ResultsAugust 7 at 6:00 AM | globenewswire.comEnovis Earnings: What To Look For From ENOVAugust 6 at 3:37 AM | finance.yahoo.comEnovis (ENOV) Expected to Announce Quarterly Earnings on ThursdayJuly 31, 2025 | americanbankingnews.com3 Reasons to Sell ENOV and 1 Stock to Buy InsteadJuly 28, 2025 | msn.comEnovis (ENOV) Stock Trades Up, Here Is WhyJuly 23, 2025 | finance.yahoo.comSee More Headlines ENOV Stock Analysis - Frequently Asked Questions How have ENOV shares performed this year? Enovis' stock was trading at $43.88 at the beginning of 2025. Since then, ENOV stock has decreased by 35.2% and is now trading at $28.4450. How were Enovis' earnings last quarter? Enovis Corporation (NYSE:ENOV) issued its earnings results on Thursday, August, 7th. The company reported $0.79 EPS for the quarter, topping the consensus estimate of $0.74 by $0.05. The business's revenue was up 7.5% compared to the same quarter last year. Read the conference call transcript. Who are Enovis' major shareholders? Enovis' top institutional investors include DAVENPORT & Co LLC (4.98%), Boston Partners (1.58%), Allspring Global Investments Holdings LLC (1.42%) and Tributary Capital Management LLC (1.06%). Insiders that own company stock include Matthew L Trerotola, Daniel A Pryor, Brady Shirley, Christopher M Hix, A Clayton Perfall, Phillip Benjamin (Ben) Berry, Patricia A Lang, Bradley J Tandy, Rajiv Vinnakota and John Kleckner. View institutional ownership trends. How do I buy shares of Enovis? Shares of ENOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Enovis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Enovis investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST). Company Calendar Today8/07/2025Last Earnings8/07/2025Next Earnings (Estimated)8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MEDICAL INFO SYS Sub-IndustryMedical Equipment Current SymbolNYSE:ENOV CIK1420800 Webwww.enovis.com Phone302-252-9160Fax301-323-9001Employees7,367Year FoundedN/APrice Target and Rating Average Price Target for Enovis$55.60 High Price Target$70.00 Low Price Target$46.00 Potential Upside/Downside+95.5%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($13.95) Trailing P/E RatioN/A Forward P/E Ratio10.20 P/E GrowthN/ANet Income-$825.49 million Net Margins-37.65% Pretax Margin-37.25% Return on Equity5.99% Return on Assets3.44% Debt Debt-to-Equity Ratio0.52 Current Ratio2.55 Quick Ratio1.32 Sales & Book Value Annual Sales$2.11 billion Price / Sales0.77 Cash Flow$20.61 per share Price / Cash Flow1.38 Book Value$45.10 per share Price / Book0.63Miscellaneous Outstanding Shares57,120,000Free Float55,581,000Market Cap$1.62 billion OptionableOptionable Beta1.70 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NYSE:ENOV) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enovis Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Enovis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.